When asked about developments, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel commented on the need to identify disease-modifying therapies. [WATCH TIME: 3 minutes]
The assistant professor of neurology at Massachusetts General Hospital and Harvard Medical School spoke about the high risk of epilepsy for the older population at the 2022 AES annual meeting. [WATCH TIME: 1 minute]
The field of Alzheimer disease has entered a new era of earlier detection, creating an opportunity to redefine treatment and the clinical care of patients.
The medical director for the Center for Brain injuries at Hackensack Meridian Health provided recommendations for clinicians to consider in the rehabilitation of women with TBI. [WATCH TIME: 6 minutes]
Although combination carbidopa-levodopa has become a standard for the treatment of many of the motor features of PD to this day, gait dysfunction remains a difficult symptom to treat.
The assistant professor of occupational therapy at the New York Institute of Technology talked about educating patients with Parkinson disease about the importance of maintaining social participation for cognitive function at ATMRD 2023. [WATCH TIME: 5 minutes]
Excessive daytime sleepiness is a hallmark of a number of sleep disorders, and ensuring the proper diagnosis and management of those presenting with it is crucial to care.
Larry Gifford, a patient living with Parkinson Disease and president of the PD Avengers, discussed sleep issues and nighttime symptoms faced by millions of patients with the disease worldwide.
The duo from the Critical Path Institute detailed the thought process behind evaluating the importance of specific biomarkers and their relation to disability progression in Alzheimer disease.
Episode 4 of the AUPN Leadership Minute features Clifton L. Gooch, MD, of the University of South Florida; and Robin Brey, MD, of the University of Texas Health Science Center at San Antonio. [WATCH TIME: 3 minutes]
A patient advocate within the ALS community discussed the importance of incorporating patients and their voices into clinical meetings and trial design to ultimately meet treatment goals. [WATCH TIME: 4 minutes]
Episode 26 of the AUPN Leadership Minute features Tracey A. Milligan, MD, of New York Medical College; and Larry B. Goldstein, MD, of University of Kentucky Medical Center. [WATCH TIME: 8 minutes]
Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.
Episode 10 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University and Robert C. Byrd Health; and Albert L. Wright, Jr., the president and CEO of West Virginia University Health System. [WATCH TIME: 4 minutes]
Panelists discuss how emerging therapeutic targets, including amyloid-beta plaques, tau protein aggregation, inflammation modulation, and mitochondrial dysfunction, offer promising approaches for disease-modifying treatments in early Alzheimer's disease.
Zoltan Mari, MD, shares advice and tips to physicians and patients for the use of wearable devices in PD.
As the most common trigeminal autonomic cephalalgia, this unilateral and severe headache is accompanied by ipsilateral autonomic features and is often challenging to treat.
The assistant professor at Duke University School of Nursing talked about a project aimed at developing a music-based mobile app to improve sleep for individuals with dementia and their caregivers. [WATCH TIME: 5 minutes]
The pediatric neurologist at Johns Hopkins Medicine provided commentary on the steps needed to improve treatment optimization in SMA, and the unanswered questions regarding the key biology of the disease.
Episode 3 of the AUPN Leadership Minute features Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas; and Mehmood Rashid, MD, of University of Toledo. [WATCH TIME: 4 minutes]
The professor of neurology at Mayo Clinic talked about how MOG antibody-associated disease can be diagnosed through specific antibody tests, highlighting its distinct clinical and MRI features. [WATCH TIME: 4 minutes]
The professor of neurology at Vanderbilt University Medical Center discussed advocating for reinstating personalized resources, expanding genetic testing, and improving transitional care in muscular dystrophy. [WATCH TIME: 5 minutes]
The CEO and cofounder of Amprion spoke about additional diagnostic uses of the αSyn seed amplification assay and its validation in the Parkinson's Progression Markers Initiative study at the 2023 AAN Annual Meeting. [WATCH TIME: 6 minutes]
The associate professor of neurology at The Ohio State University Wexner Medical Center provided insight on research assessing the use of a developed artificial intelligence/machine learning tool for automated stroke scale calculation. [WATCH TIME: 6 minutes]
The director of clinical outcomes and research development in neurology at Stanford University spoke about the paradigm shift in neuromuscular therapy interventions at the 2023 MDA conference. [WATCH TIME: 5 minutes]
Closing thoughts on advice to community neurologists treating spinal muscular atrophy (SMA).
The director of the center for gene therapy at Nationwide Children's Hospital talked about the challenges and opportunities of gene therapies for neuromuscular diseases at the 2023 MDA conference. [WATCH TIME: 4 minutes]
The headache fellow at Cleveland Clinic outlined the design and reasoning for a new study assessing nerve blocks to treat COVID-19 headache.
The clinical research associate at the University of Texas Health Science Center at San Antonio discussed a study that explores the relationship between cognitive function and gut microbiome structure in middle-aged adults from the Framingham Heart Study cohort. [WATCH TIME: 4 minutes]
This story highlights a mother’s journey through her daughter Addie's diagnosis of Tuberous Sclerosis Complex (TSC), emphasizing the critical need for early diagnosis, parental advocacy, and the strength of community support.